Date of Award

Spring 4-21-2023

Document Type


Degree Name

Master of Medical Science (MMSc)

First Advisor

Seyedtaghi Takyar, MD


Chronic Obstructive Pulmonary Disease (COPD) is a progressive irreversible disease of the airway and/or alveoli involving chronic inflammation that leads to airflow limitations, respiratory symptoms, and acute exacerbations. COPD Patients with an eosinophilic phenotype are at the highest risk for acute exacerbations and are currently treated with steroid maintenance therapy. However, some eosinophilic COPD patients continue to experience exacerbations despite the use of steroid-based inhaler therapy. This study aims to test the efficacy of anti-IL-5 add-on therapy in decreasing annual moderate to severe exacerbation rates in Eosinophilic COPD patients with elevated Serum IL-5 refractory to steroid-based triple inhaler therapy. In this two-arm, randomized, placebo-controlled, triple-blinded trial, we will assign subjects to receive either monthly mepolizumab 100mg or placebo add-on therapy and will compare mean annual exacerbation rates. Establishing a therapy regimen that decreases exacerbations will reduce the rate of pulmonary decline, morbidity, and mortality in this high-risk population.